Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series.

Rusz O, Kószó R, Dobi Á, Csenki M, Valicsek E, Nikolényi A, Uhercsák G, Cserháti A, Kahán Z.

Onco Targets Ther. 2018 Sep 4;11:5459-5463. doi: 10.2147/OTT.S170736. eCollection 2018.

2.

Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.

Xiao Q, Sun Y, Dobi A, Srivastava S, Wang W, Srivastava S, Ji Y, Hou J, Zhao GP, Li Y, Li H.

Sci Rep. 2018 Aug 27;8(1):12868. doi: 10.1038/s41598-018-30325-9.

3.

Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.

Mohamed AA, Xavier CP, Sukumar G, Tan SH, Ravindranath L, Seraj N, Kumar V, Sreenath T, McLeod DG, Petrovics G, Rosner IL, Srivastava M, Strovel J, Malhotra SV, LaRonde NA, Dobi A, Dalgard CL, Srivastava S.

Cancer Res. 2018 Jul 1;78(13):3659-3671. doi: 10.1158/0008-5472.CAN-17-2949. Epub 2018 Apr 30.

PMID:
29712692
4.

Boost Irradiation Integrated to Whole Brain Radiotherapy in the Management of Brain Metastases.

Dobi Á, Fodor E, Maráz A, Együd Z, Cserháti A, Tiszlavicz L, Reisz Z, Barzó P, Varga Z, Hideghéty K.

Pathol Oncol Res. 2018 Jan 17. doi: 10.1007/s12253-018-0383-y. [Epub ahead of print]

PMID:
29344836
5.

Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.

Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S.

Sci Rep. 2017 Sep 6;7(1):10693. doi: 10.1038/s41598-017-09612-4.

6.

Ethnicity and ERG frequency in prostate cancer.

Sedarsky J, Degon M, Srivastava S, Dobi A.

Nat Rev Urol. 2018 Feb;15(2):125-131. doi: 10.1038/nrurol.2017.140. Epub 2017 Sep 5. Review.

PMID:
28872154
7.

Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

Cullen J, Young D, Chen Y, Degon M, Farrell J, Sedarsky J, Baptiste W, Rosen P, Tolstikov V, Kiebish M, Kagan J, Srivastava S, Kuo HC, Moncur JT, Rosner IL, Narain N, Akmaev V, Petrovics G, Dobi A, McLeod DG, Srivastava S, Sesterhenn IA.

Eur Urol Focus. 2017 Mar 11. pii: S2405-4569(17)30064-0. doi: 10.1016/j.euf.2017.02.016. [Epub ahead of print]

PMID:
28753864
8.

First Searches for Axions and Axionlike Particles with the LUX Experiment.

Akerib DS, Alsum S, Aquino C, Araújo HM, Bai X, Bailey AJ, Balajthy J, Beltrame P, Bernard EP, Bernstein A, Biesiadzinski TP, Boulton EM, Brás P, Byram D, Cahn SB, Carmona-Benitez MC, Chan C, Chiller AA, Chiller C, Currie A, Cutter JE, Davison TJR, Dobi A, Dobson JEY, Druszkiewicz E, Edwards BN, Faham CH, Fallon SR, Fiorucci S, Gaitskell RJ, Gehman VM, Ghag C, Gibson KR, Gilchriese MGD, Hall CR, Hanhardt M, Haselschwardt SJ, Hertel SA, Hogan DP, Horn M, Huang DQ, Ignarra CM, Jacobsen RG, Ji W, Kamdin K, Kazkaz K, Khaitan D, Knoche R, Larsen NA, Lee C, Lenardo BG, Lesko KT, Lindote A, Lopes MI, Manalaysay A, Mannino RL, Marzioni MF, McKinsey DN, Mei DM, Mock J, Moongweluwan M, Morad JA, Murphy ASJ, Nehrkorn C, Nelson HN, Neves F, O'Sullivan K, Oliver-Mallory KC, Palladino KJ, Pease EK, Reichhart L, Rhyne C, Shaw S, Shutt TA, Silva C, Solmaz M, Solovov VN, Sorensen P, Stephenson S, Sumner TJ, Szydagis M, Taylor DJ, Taylor WC, Tennyson BP, Terman PA, Tiedt DR, To WH, Tripathi M, Tvrznikova L, Uvarov S, Velan V, Verbus JR, Webb RC, White JT, Whitis TJ, Witherell MS, Wolfs FLH, Xu J, Yazdani K, Young SK, Zhang C; LUX Collaboration.

Phys Rev Lett. 2017 Jun 30;118(26):261301. doi: 10.1103/PhysRevLett.118.261301. Epub 2017 Jun 29.

9.

Limits on Spin-Dependent WIMP-Nucleon Cross Section Obtained from the Complete LUX Exposure.

Akerib DS, Alsum S, Araújo HM, Bai X, Bailey AJ, Balajthy J, Beltrame P, Bernard EP, Bernstein A, Biesiadzinski TP, Boulton EM, Brás P, Byram D, Cahn SB, Carmona-Benitez MC, Chan C, Chiller AA, Chiller C, Currie A, Cutter JE, Davison TJR, Dobi A, Dobson JEY, Druszkiewicz E, Edwards BN, Faham CH, Fallon SR, Fiorucci S, Gaitskell RJ, Gehman VM, Ghag C, Gilchriese MGD, Hall CR, Hanhardt M, Haselschwardt SJ, Hertel SA, Hogan DP, Horn M, Huang DQ, Ignarra CM, Jacobsen RG, Ji W, Kamdin K, Kazkaz K, Khaitan D, Knoche R, Larsen NA, Lee C, Lenardo BG, Lesko KT, Lindote A, Lopes MI, Manalaysay A, Mannino RL, Marzioni MF, McKinsey DN, Mei DM, Mock J, Moongweluwan M, Morad JA, Murphy ASJ, Nehrkorn C, Nelson HN, Neves F, O'Sullivan K, Oliver-Mallory KC, Palladino KJ, Pease EK, Reichhart L, Rhyne C, Shaw S, Shutt TA, Silva C, Solmaz M, Solovov VN, Sorensen P, Stephenson S, Sumner TJ, Szydagis M, Taylor DJ, Taylor WC, Tennyson BP, Terman PA, Tiedt DR, To WH, Tripathi M, Tvrznikova L, Uvarov S, Velan V, Verbus JR, Webb RC, White JT, Whitis TJ, Witherell MS, Wolfs FLH, Xu J, Yazdani K, Young SK, Zhang C; LUX Collaboration.

Phys Rev Lett. 2017 Jun 23;118(25):251302. doi: 10.1103/PhysRevLett.118.251302. Epub 2017 Jun 23.

10.

Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.

Mohamed AA, Tan SH, Xavier CP, Katta S, Huang W, Ravindranath L, Jamal M, Li H, Srivastava M, Srivatsan ES, Sreenath TL, McLeod DG, Srinivasan A, Petrovics G, Dobi A, Srivastava S.

Mol Cancer Res. 2017 Oct;15(10):1308-1317. doi: 10.1158/1541-7786.MCR-17-0058. Epub 2017 Jun 12.

11.

ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.

Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S.

Sci Rep. 2017 Apr 24;7(1):1109. doi: 10.1038/s41598-017-01187-4. Erratum in: Sci Rep. 2017 Sep 6;7(1):10693.

12.

Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.

Rastogi A, Ali A, Tan SH, Banerjee S, Chen Y, Cullen J, Xavier CP, Mohamed AA, Ravindranath L, Srivastav J, Young D, Sesterhenn IA, Kagan J, Srivastava S, McLeod DG, Rosner IL, Petrovics G, Dobi A, Srivastava S, Srinivasan A.

Genes Cancer. 2016 Nov;7(11-12):394-413. doi: 10.18632/genesandcancer.126.

13.

Results from a Search for Dark Matter in the Complete LUX Exposure.

Akerib DS, Alsum S, Araújo HM, Bai X, Bailey AJ, Balajthy J, Beltrame P, Bernard EP, Bernstein A, Biesiadzinski TP, Boulton EM, Bramante R, Brás P, Byram D, Cahn SB, Carmona-Benitez MC, Chan C, Chiller AA, Chiller C, Currie A, Cutter JE, Davison TJ, Dobi A, Dobson JE, Druszkiewicz E, Edwards BN, Faham CH, Fiorucci S, Gaitskell RJ, Gehman VM, Ghag C, Gibson KR, Gilchriese MG, Hall CR, Hanhardt M, Haselschwardt SJ, Hertel SA, Hogan DP, Horn M, Huang DQ, Ignarra CM, Ihm M, Jacobsen RG, Ji W, Kamdin K, Kazkaz K, Khaitan D, Knoche R, Larsen NA, Lee C, Lenardo BG, Lesko KT, Lindote A, Lopes MI, Manalaysay A, Mannino RL, Marzioni MF, McKinsey DN, Mei DM, Mock J, Moongweluwan M, Morad JA, Murphy AS, Nehrkorn C, Nelson HN, Neves F, O'Sullivan K, Oliver-Mallory KC, Palladino KJ, Pease EK, Phelps P, Reichhart L, Rhyne C, Shaw S, Shutt TA, Silva C, Solmaz M, Solovov VN, Sorensen P, Stephenson S, Sumner TJ, Szydagis M, Taylor DJ, Taylor WC, Tennyson BP, Terman PA, Tiedt DR, To WH, Tripathi M, Tvrznikova L, Uvarov S, Verbus JR, Webb RC, White JT, Whitis TJ, Witherell MS, Wolfs FL, Xu J, Yazdani K, Young SK, Zhang C; LUX Collaboration.

Phys Rev Lett. 2017 Jan 13;118(2):021303. doi: 10.1103/PhysRevLett.118.021303. Epub 2017 Jan 11.

14.

Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer.

Ravipaty S, Wu W, Dalvi A, Tanna N, Andreazi J, Friss T, Klotz A, Liao C, Garren J, Schofield S, Diamandis EP, Klein EA, Dobi A, Srivastava S, Tekumalla P, Kiebish MA, Vishnudas V, Sarangarajan RP, Narain NR, Akmaev VR.

J Mol Biomark Diagn. 2017;8(2). pii: 323. doi: 10.4172/2155-9929.1000323. Epub 2017 Feb 8.

15.

Diabetes-induced hepatic oxidative stress: a new pathogenic role for glycated albumin.

Patche J, Girard D, Catan A, Boyer F, Dobi A, Planesse C, Diotel N, Guerin-Dubourg A, Baret P, Bravo SB, Paradela-Dobarro B, Álvarez E, Essop MF, Meilhac O, Bourdon E, Rondeau P.

Free Radic Biol Med. 2017 Jan;102:133-148. doi: 10.1016/j.freeradbiomed.2016.11.026. Epub 2016 Nov 24.

PMID:
27890722
16.

Results on the Spin-Dependent Scattering of Weakly Interacting Massive Particles on Nucleons from the Run 3 Data of the LUX Experiment.

Akerib DS, Araújo HM, Bai X, Bailey AJ, Balajthy J, Beltrame P, Bernard EP, Bernstein A, Biesiadzinski TP, Boulton EM, Bradley A, Bramante R, Cahn SB, Carmona-Benitez MC, Chan C, Chapman JJ, Chiller AA, Chiller C, Currie A, Cutter JE, Davison TJ, de Viveiros L, Dobi A, Dobson JE, Druszkiewicz E, Edwards BN, Faham CH, Fiorucci S, Gaitskell RJ, Gehman VM, Ghag C, Gibson KR, Gilchriese MG, Hall CR, Hanhardt M, Haselschwardt SJ, Hertel SA, Hogan DP, Horn M, Huang DQ, Ignarra CM, Ihm M, Jacobsen RG, Ji W, Kazkaz K, Khaitan D, Knoche R, Larsen NA, Lee C, Lenardo BG, Lesko KT, Lindote A, Lopes MI, Malling DC, Manalaysay A, Mannino RL, Marzioni MF, McKinsey DN, Mei DM, Mock J, Moongweluwan M, Morad JA, Murphy AS, Nehrkorn C, Nelson HN, Neves F, O'Sullivan K, Oliver-Mallory KC, Ott RA, Palladino KJ, Pangilinan M, Pease EK, Phelps P, Reichhart L, Rhyne C, Shaw S, Shutt TA, Silva C, Solovov VN, Sorensen P, Stephenson S, Sumner TJ, Szydagis M, Taylor DJ, Taylor W, Tennyson BP, Terman PA, Tiedt DR, To WH, Tripathi M, Tvrznikova L, Uvarov S, Verbus JR, Webb RC, White JT, Whitis TJ, Witherell MS, Wolfs FL, Yazdani K, Young SK, Zhang C; LUX Collaboration.

Phys Rev Lett. 2016 Apr 22;116(16):161302. doi: 10.1103/PhysRevLett.116.161302. Epub 2016 Apr 20.

17.

Improved Limits on Scattering of Weakly Interacting Massive Particles from Reanalysis of 2013 LUX Data.

Akerib DS, Araújo HM, Bai X, Bailey AJ, Balajthy J, Beltrame P, Bernard EP, Bernstein A, Biesiadzinski TP, Boulton EM, Bradley A, Bramante R, Cahn SB, Carmona-Benitez MC, Chan C, Chapman JJ, Chiller AA, Chiller C, Currie A, Cutter JE, Davison TJ, de Viveiros L, Dobi A, Dobson JE, Druszkiewicz E, Edwards BN, Faham CH, Fiorucci S, Gaitskell RJ, Gehman VM, Ghag C, Gibson KR, Gilchriese MG, Hall CR, Hanhardt M, Haselschwardt SJ, Hertel SA, Hogan DP, Horn M, Huang DQ, Ignarra CM, Ihm M, Jacobsen RG, Ji W, Kazkaz K, Khaitan D, Knoche R, Larsen NA, Lee C, Lenardo BG, Lesko KT, Lindote A, Lopes MI, Malling DC, Manalaysay A, Mannino RL, Marzioni MF, McKinsey DN, Mei DM, Mock J, Moongweluwan M, Morad JA, Murphy AS, Nehrkorn C, Nelson HN, Neves F, O'Sullivan K, Oliver-Mallory KC, Ott RA, Palladino KJ, Pangilinan M, Pease EK, Phelps P, Reichhart L, Rhyne C, Shaw S, Shutt TA, Silva C, Solovov VN, Sorensen P, Stephenson S, Sumner TJ, Szydagis M, Taylor DJ, Taylor W, Tennyson BP, Terman PA, Tiedt DR, To WH, Tripathi M, Tvrznikova L, Uvarov S, Verbus JR, Webb RC, White JT, Whitis TJ, Witherell MS, Wolfs FL, Yazdani K, Young SK, Zhang C; LUX Collaboration.

Phys Rev Lett. 2016 Apr 22;116(16):161301. doi: 10.1103/PhysRevLett.116.161301. Epub 2016 Apr 20.

18.

Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1.

Kumar P, Sharad S, Petrovics G, Mohamed A, Dobi A, Sreenath TL, Srivastava S, Biswas R.

Oncotarget. 2016 Apr 19;7(16):22791-806. doi: 10.18632/oncotarget.8061.

19.

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men.

Petrovics G, Li H, Stümpel T, Tan SH, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, Zou H, Cheng J, Dalgard CL, Zhang S, Csabai I, Kagan J, Takeda D, Loda M, Srivastava S, Scherf M, Seifert M, Gaiser T, McLeod DG, Szallasi Z, Ebner R, Werner T, Sesterhenn IA, Freedman M, Dobi A, Srivastava S.

EBioMedicine. 2015 Oct 31;2(12):1957-64. doi: 10.1016/j.ebiom.2015.10.028. eCollection 2015 Dec.

20.

Cardiac Surveillance Findings During Adjuvant and Palliative Trastuzumab Therapy in Patients with Breast Cancer.

Valicsek E, Kószó R, Dobi Á, Uhercsák G, Varga Z, Vass A, Jebelovszky É, Kahán Z.

Anticancer Res. 2015 Sep;35(9):4967-73.

PMID:
26254396
21.

[Role of 18FDG-PET/CT in the management and gross tumor volume definition for radiotherapy of head and neck cancer; single institution experiences based on long-term follow-up].

Hideghéty K, Cserháti A, Besenyi Z, Zag L, Gaál S, Együd Z, Mózes P, Szántó E, Csenki M, Rusz O, Varga Z, Dobi Á, Maráz A, Pávics L, Lengyel Z.

Magy Onkol. 2015 Jun;59(2):103-10. Epub 2015 Mar 11. Hungarian.

22.

Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors.

Dubovenko A, Serebryiskaya T, Nikolsky Y, Nikolskaya T, Perlina A, JeBailey L, Bureeva S, Katta S, Srivastava S, Dobi A, Khasanova T.

J Cancer. 2015 Apr 1;6(6):490-501. doi: 10.7150/jca.8213. eCollection 2015.

23.

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.

He J, Schepmoes AA, Shi T, Wu C, Fillmore TL, Gao Y, Smith RD, Qian WJ, Rodland KD, Liu T, Camp DG 2nd, Rastogi A, Tan SH, Yan W, Mohamed AA, Huang W, Banerjee S, Kagan J, Srivastava S, McLeod DG, Srivastava S, Petrovics G, Dobi A, Srinivasan A.

J Transl Med. 2015 Feb 12;13:54. doi: 10.1186/s12967-015-0418-z.

24.

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.

Li H, Mohamed AA, Sharad S, Umeda E, Song Y, Young D, Petrovics G, McLeod DG, Sesterhenn IA, Sreenath T, Dobi A, Srivastava S.

Oncotarget. 2015 Jun 20;6(17):15137-49.

25.

Prostate cancer marker panel with single cell sensitivity in urine.

Nickens KP, Ali A, Scoggin T, Tan SH, Ravindranath L, McLeod DG, Dobi A, Tacha D, Sesterhenn IA, Srivastava S, Petrovics G.

Prostate. 2015 Jun 15;75(9):969-75. doi: 10.1002/pros.22981. Epub 2015 Mar 23.

26.

ERG oncoprotein expression in prostate carcinoma patients of different ethnicities.

Kelly GM, Kong YH, Dobi A, Srivastava S, Sesterhenn IA, Pathmanathan R, Tan HM, Tan SH, Cheong SC.

Mol Clin Oncol. 2015 Jan;3(1):23-30. Epub 2014 Sep 18.

27.

ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.

Griner NB, Young D, Chaudhary P, Mohamed AA, Huang W, Chen Y, Sreenath T, Dobi A, Petrovics G, Vishwanatha JK, Sesterhenn IA, Srivastava S, Tan SH.

Mol Cancer Res. 2015 Feb;13(2):368-79. doi: 10.1158/1541-7786.MCR-14-0275-T. Epub 2014 Oct 24.

28.

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer.

Rastogi A, Tan SH, Mohamed AA, Chen Y, Hu Y, Petrovics G, Sreenath T, Kagan J, Srivastava S, McLeod DG, Sesterhenn IA, Srivastava S, Dobi A, Srinivasan A.

Genes Cancer. 2014 Jul;5(7-8):273-84.

29.

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.

Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, Chen Y, Ali A, Srinivasan A, McLeod DG, Yegnasubramanian S, Srivastava S, Dobi A, Petrovics G.

Epigenetics. 2014 Jun;9(6):918-27. doi: 10.4161/epi.28710. Epub 2014 Apr 2.

30.

First results from the LUX dark matter experiment at the Sanford underground research facility.

Akerib DS, Araújo HM, Bai X, Bailey AJ, Balajthy J, Bedikian S, Bernard E, Bernstein A, Bolozdynya A, Bradley A, Byram D, Cahn SB, Carmona-Benitez MC, Chan C, Chapman JJ, Chiller AA, Chiller C, Clark K, Coffey T, Currie A, Curioni A, Dazeley S, de Viveiros L, Dobi A, Dobson J, Dragowsky EM, Druszkiewicz E, Edwards B, Faham CH, Fiorucci S, Flores C, Gaitskell RJ, Gehman VM, Ghag C, Gibson KR, Gilchriese MG, Hall C, Hanhardt M, Hertel SA, Horn M, Huang DQ, Ihm M, Jacobsen RG, Kastens L, Kazkaz K, Knoche R, Kyre S, Lander R, Larsen NA, Lee C, Leonard DS, Lesko KT, Lindote A, Lopes MI, Lyashenko A, Malling DC, Mannino R, McKinsey DN, Mei DM, Mock J, Moongweluwan M, Morad J, Morii M, Murphy AS, Nehrkorn C, Nelson H, Neves F, Nikkel JA, Ott RA, Pangilinan M, Parker PD, Pease EK, Pech K, Phelps P, Reichhart L, Shutt T, Silva C, Skulski W, Sofka CJ, Solovov VN, Sorensen P, Stiegler T, O'Sullivan K, Sumner TJ, Svoboda R, Sweany M, Szydagis M, Taylor D, Tennyson B, Tiedt DR, Tripathi M, Uvarov S, Verbus JR, Walsh N, Webb R, White JT, White D, Witherell MS, Wlasenko M, Wolfs FL, Woods M, Zhang C; LUX Collaboration.

Phys Rev Lett. 2014 Mar 7;112(9):091303. Epub 2014 Mar 4.

31.

ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Gsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S, Vlajnic T, Srivastava M, Tan SH, Dobi A, Sesterhenn IA, Srivastava S, Bubendorf L, Ruiz C.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):126-31. doi: 10.1038/pcan.2013.62. Epub 2014 Jan 28.

32.

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.

Thangapazham R, Saenz F, Katta S, Mohamed AA, Tan SH, Petrovics G, Srivastava S, Dobi A.

BMC Cancer. 2014 Jan 13;14:16. doi: 10.1186/1471-2407-14-16.

33.

Anterior tumors of the prostate: clinicopathological features and outcomes.

Mygatt J, Sesterhenn I, Rosner I, Chen Y, Cullen J, Morris-Gore T, Barton J, Dobi A, Srivastava S, McLeod D, Brassell SA.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):75-80. doi: 10.1038/pcan.2013.54. Epub 2013 Dec 3.

PMID:
24296774
34.

Evaluation of ERG responsive proteome in prostate cancer.

Tan SH, Furusato B, Fang X, He F, Mohamed AA, Griner NB, Sood K, Saxena S, Katta S, Young D, Chen Y, Sreenath T, Petrovics G, Dobi A, McLeod DG, Sesterhenn IA, Saxena S, Srivastava S.

Prostate. 2014 Jan;74(1):70-89. doi: 10.1002/pros.22731. Epub 2013 Sep 21.

35.

miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.

Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, deVere White RW, Kung HJ.

Oncogene. 2014 May 8;33(19):2495-503. doi: 10.1038/onc.2013.200. Epub 2013 Jun 3.

36.

Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma.

Szász AM, Majoros A, Rosen P, Srivastava S, Dobi A, Szendrői A, Kulka J, Nyirády P.

Int Urol Nephrol. 2013 Jun;45(3):727-33. doi: 10.1007/s11255-013-0406-2. Epub 2013 May 18.

37.

Strengthening the accumbal indirect pathway promotes resilience to compulsive cocaine use.

Bock R, Shin JH, Kaplan AR, Dobi A, Markey E, Kramer PF, Gremel CM, Christensen CH, Adrover MF, Alvarez VA.

Nat Neurosci. 2013 May;16(5):632-8. doi: 10.1038/nn.3369. Epub 2013 Mar 31.

38.

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.

Rosen P, Pfister D, Young D, Petrovics G, Chen Y, Cullen J, Böhm D, Perner S, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S.

Urology. 2012 Oct;80(4):749-53. doi: 10.1016/j.urology.2012.07.001. Epub 2012 Aug 28.

39.

Search for neutrinoless double-beta decay in 136Xe with EXO-200.

Auger M, Auty DJ, Barbeau PS, Beauchamp E, Belov V, Benitez-Medina C, Breidenbach M, Brunner T, Burenkov A, Cleveland B, Cook S, Daniels T, Danilov M, Davis CG, Delaquis S, deVoe R, Dobi A, Dolinski MJ, Dolgolenko A, Dunford M, Fairbank W Jr, Farine J, Feldmeier W, Fierlinger P, Franco D, Giroux G, Gornea R, Graham K, Gratta G, Hall C, Hall K, Hargrove C, Herrin S, Hughes M, Johnson A, Johnson TN, Karelin A, Kaufman LJ, Kuchenkov A, Kumar KS, Leonard DS, Leonard F, Mackay D, MacLellan R, Marino M, Mong B, Montero Díez M, Müller AR, Neilson R, Nelson R, Odian A, Ostrovskiy I, O'Sullivan K, Ouellet C, Piepke A, Pocar A, Prescott CY, Pushkin K, Rowson PC, Russell JJ, Sabourov A, Sinclair D, Slutsky S, Stekhanov V, Tolba T, Tosi D, Twelker K, Vogel P, Vuilleumier JL, Waite A, Walton T, Weber M, Wichoski U, Wodin J, Wright JD, Yang L, Yen YR, Zeldovich OY; EXO Collaboration.

Phys Rev Lett. 2012 Jul 20;109(3):032505. Epub 2012 Jul 19.

PMID:
22861843
40.

Neural substrates for the distinct effects of presynaptic group III metabotropic glutamate receptors on extinction of contextual fear conditioning in mice.

Dobi A, Sartori SB, Busti D, Van der Putten H, Singewald N, Shigemoto R, Ferraguti F.

Neuropharmacology. 2013 Mar;66:274-89. doi: 10.1016/j.neuropharm.2012.05.025. Epub 2012 May 27.

41.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression.

Derosa CA, Furusato B, Shaheduzzaman S, Srikantan V, Wang Z, Chen Y, Seifert M, Ravindranath L, Young D, Nau M, Dobi A, Werner T, McLeod DG, Vahey MT, Sesterhenn IA, Srivastava S, Petrovics G.

Prostate Cancer Prostatic Dis. 2012 Jun;15(2):150-6. doi: 10.1038/pcan.2011.61. Epub 2011 Nov 29. Erratum in: Prostate Cancer Prostatic Dis. 2012 Jun;15(2):210. Siefert, M [corrected to Seifert, M].

PMID:
22343836
42.

Clinical potential of the ERG oncoprotein in prostate cancer.

Rosen P, Sesterhenn IA, Brassell SA, McLeod DG, Srivastava S, Dobi A.

Nat Rev Urol. 2012 Feb 14;9(3):131-7. doi: 10.1038/nrurol.2012.10. Review.

PMID:
22331093
43.

Oncogenic activation of ERG: A predominant mechanism in prostate cancer.

Sreenath TL, Dobi A, Petrovics G, Srivastava S.

J Carcinog. 2011;10:37. doi: 10.4103/1477-3163.91122. Epub 2011 Dec 31.

44.

ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.

Braun M, Goltz D, Shaikhibrahim Z, Vogel W, Böhm D, Scheble V, Sotlar K, Fend F, Tan SH, Dobi A, Kristiansen G, Wernert N, Perner S.

Prostate Cancer Prostatic Dis. 2012 Jun;15(2):165-9. doi: 10.1038/pcan.2011.67. Epub 2012 Jan 10.

PMID:
22231490
45.

Observation of two-neutrino double-beta decay in 136Xe with the EXO-200 detector.

Ackerman N, Aharmim B, Auger M, Auty DJ, Barbeau PS, Barry K, Bartoszek L, Beauchamp E, Belov V, Benitez-Medina C, Breidenbach M, Burenkov A, Cleveland B, Conley R, Conti E, Cook J, Cook S, Coppens A, Counts I, Craddock W, Daniels T, Danilov MV, Davis CG, Davis J, deVoe R, Djurcic Z, Dobi A, Dolgolenko AG, Dolinski MJ, Donato K, Dunford M, Fairbank W Jr, Farine J, Fierlinger P, Franco D, Freytag D, Giroux G, Gornea R, Graham K, Gratta G, Green MP, Hägemann C, Hall C, Hall K, Haller G, Hargrove C, Herbst R, Herrin S, Hodgson J, Hughes M, Johnson A, Karelin A, Kaufman LJ, Koffas T, Kuchenkov A, Kumar A, Kumar KS, Leonard DS, Leonard F, LePort F, Mackay D, MacLellan R, Marino M, Martin Y, Mong B, Díez MM, Morgan P, Müller AR, Neilson R, Nelson R, Odian A, O'Sullivan K, Ouellet C, Piepke A, Pocar A, Prescott CY, Pushkin K, Rivas A, Rollin E, Rowson PC, Russell JJ, Sabourov A, Sinclair D, Skarpaas K, Slutsky S, Stekhanov V, Strickland V, Swift M, Tosi D, Twelker K, Vogel P, Vuilleumier JL, Vuilleumier JM, Waite A, Waldman S, Walton T, Wamba K, Weber M, Wichoski U, Wodin J, Wright JD, Yang L, Yen YR, Zeldovich OY; EXO Collaboration.

Phys Rev Lett. 2011 Nov 18;107(21):212501. Epub 2011 Nov 17.

PMID:
22181874
46.

A magnetically driven piston pump for ultra-clean applications.

LePort F, Neilson R, Barbeau PS, Barry K, Bartoszek L, Counts I, Davis J, deVoe R, Dolinski MJ, Gratta G, Green M, Montero Díez M, Müller AR, O'Sullivan K, Rivas A, Twelker K, Aharmim B, Auger M, Belov V, Benitez-Medina C, Breidenbach M, Burenkov A, Cleveland B, Conley R, Cook J, Cook S, Craddock W, Daniels T, Dixit M, Dobi A, Donato K, Fairbank W Jr, Farine J, Fierlinger P, Franco D, Giroux G, Gornea R, Graham K, Green C, Hägemann C, Hall C, Hall K, Hallman D, Hargrove C, Herrin S, Hughes M, Hodgson J, Juget F, Kaufman LJ, Karelin A, Ku J, Kuchenkov A, Kumar K, Leonard DS, Lutter G, Mackay D, MacLellan R, Marino M, Mong B, Morgan P, Odian A, Piepke A, Pocar A, Prescott CY, Pushkin K, Rollin E, Rowson PC, Schmoll B, Sinclair D, Skarpaas K, Slutsky S, Stekhanov V, Strickland V, Swift M, Vuilleumier JL, Vuilleumier JM, Wichoski U, Wodin J, Yang L, Yen YR.

Rev Sci Instrum. 2011 Oct;82(10):105114. doi: 10.1063/1.3653391.

PMID:
22047336
47.

Words of wisdom. Re: Antibody-based detection of ERG rearrangement-positive prostate cancer.

McLeod DG, Dobi A.

Eur Urol. 2011 Nov;60(5):1123. doi: 10.1016/j.eururo.2011.08.036. No abstract available.

PMID:
21961743
48.

Prostate cancer: diagnostic performance of the PCA3 urine test.

Lee GL, Dobi A, Srivastava S.

Nat Rev Urol. 2011 Mar;8(3):123-4. doi: 10.1038/nrurol.2011.10. No abstract available.

PMID:
21394175
49.

ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.

Miettinen M, Wang ZF, Paetau A, Tan SH, Dobi A, Srivastava S, Sesterhenn I.

Am J Surg Pathol. 2011 Mar;35(3):432-41. doi: 10.1097/PAS.0b013e318206b67b.

PMID:
21317715
50.

Cocaine-induced plasticity in the nucleus accumbens is cell specific and develops without prolonged withdrawal.

Dobi A, Seabold GK, Christensen CH, Bock R, Alvarez VA.

J Neurosci. 2011 Feb 2;31(5):1895-904. doi: 10.1523/JNEUROSCI.5375-10.2011.

Supplemental Content

Support Center